Acumen Pharma to Present at J.P. Morgan Healthcare Conference

Ticker: ABOS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1576885

Acumen Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: conference, investor-relations, corporate-event

TL;DR

**Acumen Pharma is presenting at a major healthcare conference, expect potential news or updates.**

AI Summary

Acumen Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose its participation in the 42nd Annual J.P. Morgan Healthcare Conference. During this event, the company's management will present and engage with investors and analysts. This matters to investors because it's an opportunity for Acumen to share updates on its drug development, potentially influencing investor sentiment and the stock price (ABOS).

Why It Matters

This filing signals Acumen's active engagement with the investment community, which can increase visibility and potentially attract new investors or provide updates to current shareholders.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure about a conference presentation and does not inherently carry significant financial risk.

Analyst Insight

A smart investor would monitor news and presentations from Acumen Pharmaceuticals, Inc. during the J.P. Morgan Healthcare Conference for any significant announcements regarding their drug development or financial outlook, as these could impact the stock (ABOS).

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of Acumen Pharmaceuticals, Inc.'s 8-K filing on January 8, 2024?

The purpose of the 8-K filing is to disclose that Acumen Pharmaceuticals, Inc. will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, where its management will present and engage with investors and analysts.

What is the trading symbol for Acumen Pharmaceuticals, Inc.?

The trading symbol for Acumen Pharmaceuticals, Inc. is ABOS, and its common stock is registered on The Nasdaq Global Select Market.

What is the address of Acumen Pharmaceuticals, Inc.'s principal executive offices?

The address of Acumen Pharmaceuticals, Inc.'s principal executive offices is 427 Park St., Charlottesville, Virginia 22902.

Under which SEC Act is this 8-K filed?

This 8-K is filed under the Securities Exchange Act of 1934, pursuant to Section 13 or 15(d).

What is the Central Index Key (CIK) for Acumen Pharmaceuticals, Inc.?

The Central Index Key (CIK) for Acumen Pharmaceuticals, Inc. is 0001576885.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-08 08:33:43

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Acumen Pharmaceuticals, Inc. (the " Company ") posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. This corporate presentation was updated to include additional biomarker data relating to ACU193. A copy of the corporate presentation is attached as Exhibit 99.1 to this Report. The information in this Item 7.01 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: January 8, 2024 By: /s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing